Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21190333 | 0.80 | HPGD (0.39) | HPGDMEN1KMT2AHDAC1HDAC2 | |
| SCHEMBL21179153 | 0.74 | LMNA (0.45) | MEN1KMT2AALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL21190350 | 0.73 | LMNA (0.34) | MEN1KMT2AHSP90AA1ALDH1A1CYP2C9 | |
| SCHEMBL21179078 | 0.73 | LMNA (0.34) | MEN1KMT2AHSP90AA1ALDH1A1CYP2C9 | |
| SCHEMBL6363661 | 0.70 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL6358756 | 0.70 | ALDH1A1 (0.34) | HPGDKMT2AALDH1A1 | |
| SCHEMBL6370802 | 0.68 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL6364960 | 0.67 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL21190332 | 0.67 | KMT2A (0.46) | MEN1KMT2AALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL6364958 | 0.66 | ALDH1A1 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427550-B2 | 5-fluorouracil compounds | NUCORION PHARMACEUTICALS, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20200399227-A1 | 5-FLUOROURACIL COMPOUNDS | NUCORION PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
| WO-2019143860-A1 | 5-FLUOROURACIL COMPOUNDS | NUCORION PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399227-A1 | 5-FLUOROURACIL COMPOUNDS | DPYD, DHFR, FAU | HPGD 416/4885MEN1 447/4885KMT2A 2793/4885 |
| US-11427550-B2 | 5-fluorouracil compounds | DPYD, DHFR, MTHFD1 | HPGD 162/4885MEN1 588/4885KMT2A 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.